Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Sam Chun Dang Pharm Co., Ltd. is a notable pharmaceutical company involved in the research, development, and production of various healthcare solutions. Founded in South Korea, the company focuses on creating a diverse array of pharmaceutical products that cater to the healthcare needs of a broad spectrum of patients. Their portfolio includes over-the-counter drugs, prescription medications, and a range of health supplements, demonstrating their commitment to improving public health and optimizing therapeutic outcomes. By participating actively in the pharmaceutical industry, Sam Chun Dang Pharm Co., Ltd. contributes significantly to the accessibility and availability of essential medications across regional and global markets. The company consistently invests in innovation and manufacturing excellence, ensuring compliance with international regulatory standards and thereby enhancing its market reputation. Its role in the healthcare sector is pivotal, as it addresses critical medical needs and supports the overall advancement of medical sciences.
₩204,000.00
₩19,500.00 (-8.72%)
Live · 05:27 PM
Operating margin is thin at 3.65%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 9.9%, steady but not accelerating.
At 377x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -₩49.79B. The business is consuming cash, not generating it.
377.1x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩246.05B
▲ +9.9% YoY
Net Income (TTM)
₩17.66B
▲ +336.9% YoY
Op. Margin
5.38%
▲ +2.4pp YoY
ROIC
1.95%
▲ +1.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩71.24B
▼ -155.0% YoY
Op. Cash Flow (TTM)
-₩91M
▲ +127.3% YoY
Net Debt
-₩59.23B
Net Cash Position
Cash & Equiv.
₩129.06B
3Y CAGR: +9.3%
Continue Research
At a P/E of 377.1, Sam Chun Dang Pharm Co. (000250.XKRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Sam Chun Dang Pharm Co. scores 28/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.1%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Sam Chun Dang Pharm Co. scores 28 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 5.4% operating margin and a 2.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Sam Chun Dang Pharm Co. pays a regular dividend of about KRW 198.92 per share per year (typically in quarterly installments), a yield of roughly 0.1% at the current price. That is a payout ratio of about 26.3% of earnings, so the dividend is amply covered by earnings. Sam Chun Dang Pharm Co. has grown the dividend at roughly 48.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 000250.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 000250.XKRX's valuation and scores 28/100 on quality (lower-quality). It also yields about 0.1%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.